U.S. Generic Sterile Injectable Market
- 2026 年市場規模
- USD 23,019.2 Mn
- 2033 年預估規模
- USD 38,797.8 Mn
- 年複合成長率 CAGR
- 11%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
U.S. Generic Sterile Injectable Market,By Product (Monoclonal Antibodies, Peptide Hormones, Antibiotics, Chemotherapy Agents, and Others), By Therapeutic Application (Oncology, Metabolic Disorders, Cardiovascular Diseases, Musculoskeletal Disorders, Autoimmune Disorders, Neurological Disorders, Respiratory Disorders, Bacterial Disorders, and Others (Viral Disorders, etc.)), By Route of Administration (Intravenous, Intramuscular, Subcutaneous, and Others (Intradermal, etc.)), By Packaging Type (Vials, Ampoules, Prefilled Syringes, Cartridges, and IV Bags), By Age Group (Pediatric, Adult, and Geriatric), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
報告摘要
The U.S. generic sterile injectable market is estimated to be valued at USD 23,019.2 Mn in 2026 and is expected to reach USD 38,797.8 Mn by 2033, exhibiting a compound annual growth rate (CAGR) of 11% from 2026 to 2033. The U.S. generic sterile injectable market represents a critical segment of the pharmaceutical industry, encompassing a broad spectrum of parenteral drug formulations that are administered intravenously, intramuscularly, or subcutaneously. These sterile injectable products are bioequivalent alternatives to branded reference drugs that have lost patent protection, offering cost-effective treatment solutions across diverse therapeutic areas including oncology, cardiovascular diseases, infectious diseases, and critical care.
The market has experienced substantial growth driven by increasing healthcare costs, rising demand for affordable medications, and the expiration of patents for numerous blockbuster drugs. Generic sterile injectables require sophisticated manufacturing capabilities due to stringent regulatory requirements, complex aseptic processing, and the need for specialized packaging and storage conditions.
The U.S. Food and Drug Administration (FDA) maintain rigorous quality standards through Abbreviated New Drug Applications (ANDAs) and comprehensive facility inspections, ensuring product safety and efficacy. Market participants include established generic manufacturers, contract development and manufacturing organizations (CDMOs), and specialty pharmaceutical companies that have invested heavily in sterile manufacturing infrastructure. The sector plays a vital role in hospital and clinical settings where immediate bioavailability and precise dosing are essential, particularly in emergency care, surgical procedures, and chronic disease management, making it an indispensable component of the American healthcare system.
Market Dynamics
The U.S. generic sterile injectable market experiences robust growth driven by multiple compelling factors, with patent cliff dynamics serving as a primary catalyst as numerous high-value branded injectable drugs lose exclusivity, creating substantial opportunities for generic manufacturers to capture market share through cost-effective alternatives. Healthcare cost containment pressures from government programs, insurance providers, and hospital systems significantly drive demand for generic sterile injectables, as these products typically offer 60-90% cost savings compared to branded equivalents while maintaining therapeutic efficacy. The aging population and increasing prevalence of chronic diseases such as diabetes, cancer, and cardiovascular conditions fuel sustained demand for injectable therapies, while hospital consolidation trends create larger purchasing networks that favor generic products for formulary inclusion.
However, the market faces considerable restraints including substantial capital investment requirements for establishing and maintaining sterile manufacturing facilities that comply with FDA's stringent Current Good Manufacturing Practice (cGMP) regulations.
Complex regulatory pathways for ANDA approvals, particularly for complex generics and biosimilars, create significant barriers to entry and extend product development timelines. Supply chain vulnerabilities have been exposed through raw material shortages, manufacturing disruptions, and quality issues leading to facility shutdowns, creating drug shortages that impact market stability. Manufacturing complexities associated with maintaining sterility, cold chain requirements, and specialized packaging increase operational costs and technical risks.
Nevertheless, substantial opportunities emerge from the expanding pipeline of off-patent biologics and complex injectables, technological advancements in manufacturing processes, and growing demand for ready-to-use formulations that improve hospital workflow efficiency and reduce medication errors.
Key Features of the Study
• This report provides in-depth analysis of the U.S. generic sterile injectable market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the U.S. generic sterile injectable market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Pfizer Inc, Hikma Pharmaceuticals USA Inc, Fresenius Kabi USA LLC, Sandoz Inc, Viatris Inc, Amneal Pharmaceuticals Inc, Accord Healthcare Inc, Eugia Pharma Specialities Ltd, Dr Reddy’s Laboratories Inc, Nexus Pharmaceuticals Inc, Exela Pharma Sciences LLC, American Regent Inc, Apotex Corp, Gland Pharma Ltd, and Sun Pharmaceutical Industries Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The U.S. generic sterile injectable market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. generic sterile injectable market
Market Segmentation
• Product Insights (Revenue, USD Mn, 2021 - 2033)
o Monoclonal Antibodies
o Peptide Hormones
o Antibiotics
o Chemotherapy Agents
o Others
• Therapeutic Application Insights (Revenue, USD Mn, 2021 - 2033)
o Oncology
o Metabolic Disorders
o Cardiovascular Diseases
o Musculoskeletal Disorders
o Autoimmune Disorders
o Neurological Disorders
o Respiratory Disorders
o Bacterial Disorders
o Others (Viral Disorders, etc.)
• Route of Administration Insights (Revenue, USD Mn, 2021 - 2033)
o Intravenous
o Intramuscular
o Subcutaneous
o Others (Intradermal, etc.)
• Packaging Type Insights (Revenue, USD Mn, 2021 - 2033)
o Vials
o Ampoules
o Prefilled Syringes
o Cartridges
o IV Bags
• Age Group Insights (Revenue, USD Mn, 2021 - 2033)
o Pediatric
o Adult
o Geriatric
• Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• Key Players Insights
o Pfizer Inc
o Hikma Pharmaceuticals USA Inc
o Fresenius Kabi USA LLC
o Sandoz Inc
o Viatris Inc
o Amneal Pharmaceuticals Inc
o Accord Healthcare Inc
o Eugia Pharma Specialities Ltd
o Dr Reddy’s Laboratories Inc
o Nexus Pharmaceuticals Inc
o Exela Pharma Sciences LLC
o American Regent Inc
o Apotex Corp
o Gland Pharma Ltd
o Sun Pharmaceutical Industries Ltd
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
Market Definition and Scope
o Executive Summary
U.S. Generic Sterile Injectable Market, By Product
U.S. Generic Sterile Injectable Market, By Therapeutic Application
U.S. Generic Sterile Injectable Market, By Route of Administration
U.S. Generic Sterile Injectable Market, By Packaging Type
U.S. Generic Sterile Injectable Market, By Age Group
U.S. Generic Sterile Injectable Market, By Distribution Channel
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
o Impact Analysis
o Key Highlights
o Regulatory Scenario
o Product Launches/Approvals
o PEST Analysis
o PORTER’s Analysis
o Market Opportunities
o Regulatory Scenario
o Key Developments
o Industry Trends
4. U.S. Generic Sterile Injectable Market, By Product, 2021-2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Monoclonal Antibodies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Peptide Hormones
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Antibiotics
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Chemotherapy Agents
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
5. U.S. Generic Sterile Injectable Market, By Therapeutic Application, 2021-2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Oncology
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Metabolic Disorders
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Cardiovascular Diseases
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Musculoskeletal Disorders
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Autoimmune Disorders
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Neurological Disorders
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Respiratory Disorders
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Bacterial Disorders
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Others (Viral Disorders, etc.)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
6. U.S. Generic Sterile Injectable Market, By Route of Administration, 2021-2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Intravenous
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Intramuscular
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Subcutaneous
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Others (Intradermal, etc.)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
7. U.S. Generic Sterile Injectable Market, By Packaging Type, 2021-2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Vials
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Ampoules
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Prefilled Syringes
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Cartridges
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o IV Bags
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
8. U.S. Generic Sterile Injectable Market, By Age Group, 2021-2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Pediatric
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Adult
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Geriatric
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
9. U.S. Generic Sterile Injectable Market, By Distribution Channel, 2021-2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
10. 10. Competitive Landscape
o Pfizer Inc
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Hikma Pharmaceuticals USA Inc
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Fresenius Kabi USA LLC
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Sandoz Inc
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Viatris Inc
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Amneal Pharmaceuticals Inc
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Accord Healthcare Inc
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Eugia Pharma Specialities Ltd
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Dr Reddy’s Laboratories Inc
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Nexus Pharmaceuticals Inc
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Exela Pharma Sciences LLC
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o American Regent Inc
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Apotex Corp
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Gland Pharma Ltd
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Sun Pharmaceutical Industries Ltd
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
11. Analyst Recommendations
o Wheel of Fortune
o Analyst View
o Coherent Opportunity Map
12. References and Research Methodology
o References
o Research Methodology
o About us
*Browse 32 market data tables and 28 figures on 'Generic Sterile Injectable Market' - U.S. forecast to 2033
提及公司
同分類最新報告（醫療器材）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們